Skip to navigation Skip to content

Targeted Request for Applications


This RFA is now closed. When another targeted research opportunity is open for applications, it will be posted here.

RFA: Generating Knowledge and Tools to Promote Remyelination and Neuroprotection in Multiple Sclerosis

The National MS Society is pleased to announce the release of a new Request for Applications focusing on Generating Knowledge and Tools to Promote Remyelination and Neuroprotection in Multiple Sclerosis intended to support research that advances our Pathways to Cures Roadmap. 

This RFA is open to not-for-profit academic research institutions worldwide. Collaborations with commercial organizations are allowed.
Purpose of this RFA: This funding concept supports research that addresses gaps in our knowledge of the underlying biology of CNS remyelination in MS, the factors or processes that modulate this process, and methods to measure remyelination. Additionally, research into neuroprotective mechanisms with the potential to prolong neuronal viability for remyelination is encouraged. The supported research is intended to lay the foundation for the next generation of therapeutic approaches. 

In addition, the concept supports the development or refinement of tools needed to support preclinical and clinical studies of remyelination and neuroprotection in MS, including in vitro and animal models that more closely reflect MS pathophysiology and clinical biomarkers with utility for measuring CNS myelination and neuroprotection. Applications proposing the testing of new or established biomarkers must include relevant components of analytical method validation to ensure that a test, tool, or instrument is adequate for its proposed context of use.

Areas of specific interest may include but are not limited to:
• Studies of mechanisms underlying endogenous remyelination in MS.
• Investigations into the basis of the heterogeneity of endogenous remyelination observed across lesion types and between individuals living with MS. 
• Studies of factors that modulate remyelination in MS.
• Studies of mechanisms to provide neuroprotection or oligodendrocyte protection.
• In vivo and in vitro model systems that more closely mimic MS pathology with utility to study interventions supporting remyelination.
• Clinically translatable biomarkers for the measurement of remyelination or neuroprotection.
• Preclinical proof of concept studies for potential therapeutic targets to promote remyelination or neuroprotection. Studies could involve small molecule drugs, cell-based strategies, biologics, genetic models, or other suitable approaches.

Areas not supported by this RFA include:
• Studies addressing developmental myelination.
• Investigation of neurodegenerative mechanisms without a therapeutic focus.
• Studies of the adaptive immune system unrelated to remyelination. 
• Studies of anti-inflammatory mechanisms that indirectly create an environment conducive to repair.

Funding:  Up to $1,000,000 USD total costs (including indirect costs where applicable) for up to 3 years of support will be provided and must be justified based on the scientific work plan.  Eligibility
Applicants should possess an M.D., Ph.D. or equivalent and be considered eligible by their institution to apply for grant support. Postdoctoral fellows, residents and other trainees are not eligible to apply.

A brief pre-application is required to determine if a proposal is aligned with the objectives of the RFA. Potential applicants are strongly encouraged to consult with Society scientific staff prior to submitting a proposal (see contact information below). Upon review of pre-applications by staff, applicants proposing work that is aligned with the RFA objectives will be invited to submit full applications.

NEW Deadlines:
Pre-applications will be accepted beginning: October 5, 2023
Pre-Application Deadline: 5:00 PM Eastern, Wednesday, January 3, 2024
Full Application Deadline: 5:00 PM Eastern, Wednesday, January 10, 2024

Applicants are encouraged to contact research staff for more information about this RFA:

Walt Kostich, PhD
Senior Director, Translational Research

James Quinn, PhD                   
Director, Biomedical Research


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.